NOV 05, 2018 10:39 AM PST

Anti-Parasitic Drug Improves Long-term Clinical Outcomes in Chagas Disease

WRITTEN BY: Nouran Amin

In a recent study published in PLOS Neglected Tropical Diseases, an anti-parasite drug by the name of ‘benznidazole’ may hold potential in improving the long-term prognoses of patients with chronic Chagas disease.

Trypansosoma cruzi, the parasite that causes Chagas disease.

Found mainly in endemic areas, Chagas disease is a life-threatening illness caused by the parasite Trypanosoma cruzi (T. cruzi) and is the leading cause of cardiopathy and death in Latin America. Currently, about 6 million to 7 million people worldwide are affected by Chagas disease. Parasitic transmission to humans is through contact with feces or urine of triatomine bugs, also known as 'kissing bugs'.

Few treatments exist to patients of Chagas diseases and among those known treatment options—the specific therapeutic benefits are not understood. In a comprehensive study, scientists in Brazil studied 1,813 patients who had tested positive for the parasite T. cruzi. They then compared clinical outcomes of two groups: those who had previously received benznidazole treatments and those who had not taken any benznidazole.

After a two year follow-up period, results of the study indicated that those patients that were treated with benznidazole in the early stages of the disease-- had improved clinical and parasitological outcomes. However, during the same period those patients that did not receive the benznidazole treatment had lower mortality rates, lower parasite counts, and a reduced risk of any Chagas-related heart disease.

The study demonstrated a marked clinical benefit from benznidazole and according to the researchers, further study is needed to learn more about the duration and dose need for effective treatment.

Even though the study holds limitations, researchers urge health care professionals to treat Chagas patients with benznidazole in the early-stages of the disease: "Because there are millions of untreated ChD patients in the world and no new treatments are available for the foreseeable future, it is reasonable to consider treating all Chagas disease patients without advanced cardiopathy with benznidazole, especially those who are less than 50 years of age."

 

Story Source: PLOS, WHO

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 05, 2018
Microbiology
NOV 05, 2018
Potential Antidote to Botulism is Found
A microbe called Clostridium botulinum and sometimes two other strains of Clostridium bacteria can make a toxic chemical called botulism....
NOV 07, 2018
Drug Discovery
NOV 07, 2018
Zebrafish Bacterial Gut Protein Delays Death by Septic Shock
At the University of Oregon, researchers identified a novel anti-inflammatory protein that is secreted by the common gut bacterium in zebrafish. The protei...
NOV 21, 2018
Microbiology
NOV 21, 2018
Human Antibody That can Neutralize West Nile Virus is Found
In 1999, there were 62 cases of West Nile Virus in New York State. Since then it has spread around the United States....
DEC 05, 2018
Videos
DEC 05, 2018
Male Contraceptive Gel is in Clinical Trials
Researchers have started a clinical trial involving 420 participants to test the efficacy of a male contraceptive gel....
DEC 17, 2018
Drug Discovery
DEC 17, 2018
Nanocapsules Improve The Delivery of Antiparasitic Drugs
The efficacy of antiparasitic medications highly depends on how they dissolve and are absorbed by the body—limiting the therapeutic potential of trad...
JAN 27, 2019
Microbiology
JAN 27, 2019
Alzheimer's Linked to a Gum Disease-associated Bacterium
Alzheimer's is more likely in the aged, but the exact causes were unclear. New work shows that it may stem from a brain infection....
Loading Comments...